Case Study 1

Pre-clinical Acceleration & Botanical Drug Packaging

01 / 09

Ganoderma lucidum

Institutional Funding & Collaborative Frameworks:

Competitive Public Research Grants — Funded via competitive national-tier General Research Funds (GRFs).
Institutional R&D Backing — Supported through Central Research Grants under advanced health technology frameworks.
Clinical Co-Investigators — Prof. Chi-Fai Ng & Prof. Jeremy Teoh | Urology, Chinese University of Hong Kong (Long-term collaborators)

Commercial (Pharma, Biotech & Life Science) | Core Domains: Oncology, Botanical Pharmacology)
Academic (Researchers, PhD students) | Core Domains: Oncology, Urology, Immunology, Biochemistry)

The Problem: Botanical drug developers face steep regulatory barriers in transitioning natural compounds into formal pipelines. Without rigorous mechanism mapping and comparative toxicity profiles against standard-of-care options, compounds fail to secure clinical backing.
The Intervention: SPECTRA engineered a multi-stage testing matrix evaluating Ganoderma lucidum. This involved establishing syngeneic premalignant cell lines to map cytokine gene induction, building live-imaging orthotropic murine bladder cancer models, and quantifying comparative safety benchmarks directly against standard clinical immunotherapy (BCG).
Core Methodological Niche: In-vivo disease modelling & murine line.
The Outcome: Successfully mapped the tumour-inhibitory pathways and cytokine regulations required for regulatory drug asset portfolios. The protocol design secured consecutive competitive government funding and established deep publication authority in high-impact ethnopharmacology journals.